Multicenter phase ii study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG)

Table 3 Multi-factor analysis of risk factors for acute graft-versus-host disease determined

Variable	N	Grade 2–4 aGVHD			Grade 3–4 aGVHD
Variable	N	HR	95% CI	P	HR	95% CI	P
Age for recipients,years
<40	305	1.00			1.00
≥40	189	1.65	1.13-2.41	0.010	1.19	0.66-2.14	0.565
Conditioning regimen
BuCy	341	1.00			1.00
TBICy	24	1.67	0.76-3.71	0.205	1.71	0.50-4.61	0.395
BuFlu	128	1.58	1.04-2.39	0.033	2.49	1.35-4.61	0.004
Disease stage
Non-advanced	429	1.00			1.00
Advanced	65	1.44	0.85-2.43	0.172	2.45	1.26-4.78	0.009

aGVHD, acute graft-versus-host disease; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; Flu, fludarabin; Non-advanced stage, including acute leukemia (AL) in CR, CML in CP and AP, MDS-RAEB; Advanced stage, including AL in NR and CML in BC.

ISSN: 1756-8722